About the EVOKE-01 Study The EVOKE-01 study is a global, multi-center, open-label Phase 3 study randomized 1:1 to evaluate Trodelvy vs. docetaxel in patients with advanced or metastatic NSCLC that has progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. The st...
Jan 2024 Press Release; Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC) ASCO 2024 Data: Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lun...